替格瑞洛在冠脉介入治疗后的治疗效果及安全性临床观察

黄强??李明琰

[摘要] 目的 观察替格瑞洛在冠心病冠脈介入治疗后的安全性。 方法 选取2015年1～12月期间在我院进行治疗的50例冠心病冠脉介入治疗后患者作为研究对象，根据临床治疗方案的不同分为两组，其中对照组25例患者采用阿司匹林肠溶片+氯吡格雷双抗血小板进行治疗，观察组25例患者采用替格瑞洛+阿司匹林肠溶片双抗血小板进行治疗。比较两治疗组患者的临床治疗效果、心血管不良事件（MACE）及不良反应发生率。 结果 研究组有效率为96%，对照组为92%，差异无统计学意义（P>0.05）；研究组的MACE发生率为8%，对照组为8%，差异无统计学意义（P>0.05）；研究组的不良反应发生率为12%，对照组为12%，差异无统计学意义（P>0.05）。 结论 替格瑞洛在冠脉介入治疗后的临床使用治疗效果与氯吡格雷无明显的差别，心血管不良事件（MACE）发生率无明显的差别。出血不良反应无明显的差别，但观察中替格瑞洛发生呼吸困难的1例。

[关键词] 替格瑞洛；氯吡格雷；冠脉介入治疗；临床疗效；安全性

[中图分类号] R541.4 [文献标识码] A [文章编号] 2095-0616（2017）12-39-04

Clinical efficacy and safety observation of ticagrelor and clopidogrel after percutaneous coronary intervention

HUANG Qiang LI Mingyan

The Second Affiliated Hospital of Guangzhou Medical University，Guangzhou 511447，China

[Abstract] Objective To observe the safety of the treatment of coronary heart disease （CHD） after percutaneous coronary intervention （PCI）. Methods 50 cases of coronary artery interventional therapy after treatment of patients in our hospital from January 2015 to December 2015 were selected as the research object.They were divided into two groups according to different clinical treatment.Patients in the control group （25 cases） were treated with Aspirin Enteric-coated Tablets+clopidogrel dual antiplatelet therapy，and patients in the study group （25 cases） were treated with ticagrelor Aspirin Enteric-coated Tablets+dual antiplatelet therapy.The clinical therapeutic effect，adverse cardiovascular events （MACE） and adverse reactions were compared between the two groups. Results The effective rate of study group was 96%，which was 92% in the control group，and the difference was not statistically significant （P>0.05）.The incidence rate of MACE of study group was 8%，which was 8% in the control group，the difference was not statistically significant （P>0.05）.The incidence of adverse reactions of the study group was 12%，and the control group's also 12.0%，there was no statistically significant difference between groups （P>0.05）. Conclusion There was no significant difference between Ti Gray Lo and clopidogrel in the clinical use of coronary intervention，and there was no significant difference in the incidence of cardiovascular adverse events （MACE）.There were no significant differences in the adverse effects of bleeding，but 1 cases of dyspnea were observed in Grillo.

[Key words] Grillo；Clopidogrel；Percutaneous coronary intervention；Clinical efficacy；Safety

冠心病全称为冠状动脉硬化性心脏病，其由冠状动脉粥样硬化出现狭窄、堵塞或痉挛所致心肌缺血或坏死引起的心脏病[1]。自1997年经皮腔内冠状动脉成形术（PTCA）成功后，其标志冠心病进入介入治疗的时代，冠心病以提高心肌血流灌注、开通冠状动脉管腔为治疗原则，有效提高疗效，减少冠心病病死风险[2]。冠脉介入术后的抗血小板药物的使用，对术后的疗效起到非常重要的作用。替格瑞……